Medpace Holdings (STU:01P) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:01P Medpace Holdings Inc STU:01P
91 GF Score
Price €531.80
GF Value €469.66
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medpace Holdings Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Medpace Holdings  (STU:01P) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Medpace Holdings Cyclically Adjusted PS Ratio Related Terms


Medpace Holdings Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Medpace Holdings's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medpace Holdings Cyclically Adjusted PS Ratio Chart

Medpace Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 10.88 11.72 10.83 12.94

Medpace Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.84 11.94 12.90 10.39 11.02

STU:01P vs RVTY, CRL, ICLR: Cyclically Adjusted PS Ratio Comparison

For the Diagnostics & Research subindustry, Medpace Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medpace Holdings Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medpace Holdings's Cyclically Adjusted PS Ratio falls into.


STU:01P
91GF Score
Medpace Holdings Inc STU:01P
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medpace Holdings Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Medpace Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Medpace Holdings's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=21.305/333.9520*333.9520
=21.305

Current CPI (Jun. 2026) = 333.9520.

Medpace Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.567 241.428 3.551
201612 2.469 241.432 3.415
201703 2.410 243.801 3.301
201706 2.364 244.955 3.223
201709 2.397 246.819 3.243
201712 2.535 246.524 3.434
201803 3.640 249.554 4.871
201806 3.895 251.989 5.162
201809 4.151 252.439 5.491
201812 4.526 251.233 6.016
201903 4.742 254.202 6.230
201906 5.096 256.143 6.644
201909 5.140 256.759 6.685
201912 5.475 256.974 7.115
202003 5.511 258.115 7.130
202006 4.987 257.797 6.460
202009 5.223 260.280 6.701
202012 5.785 260.474 7.417
202103 5.718 264.877 7.209
202106 6.125 271.696 7.528
202109 6.683 274.310 8.136
202112 7.153 278.802 8.568
202203 8.113 287.504 9.424
202206 9.780 296.311 11.022
202209 11.812 296.808 13.290
202212 11.923 296.797 13.416
202303 12.582 301.836 13.921
202306 13.411 305.109 14.679
202309 14.253 307.789 15.465
202312 14.566 306.746 15.858
202403 14.714 312.332 15.733
202406 15.288 314.175 16.250
202409 15.130 315.301 16.025
202412 15.783 315.605 16.701
202503 17.013 319.799 17.766
202506 18.264 322.561 18.909
202509 19.595 324.800 20.147
202512 21.015 324.054 21.657
202603 20.854 330.213 21.090
202606 21.305 333.952 21.305

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Medpace Holdings (STU:01P) Overvalued in 2026?

Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued. The current stock price of €531.80 is trading 13.2% above its estimated GF Value™ of €469.66. GuruFocus considers Medpace Holdings to be Modestly Overvalued.

Key valuation signals for STU:01P:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €469.66 vs. price of €531.80 (13.2% above fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the STU:01P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medpace Holdings Business Description

Address 5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
91GF Score

Get the complete analysis for STU:01P

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€531.80
Price
€469.66
GF Value